Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734067 | 0.76 | ALDH1A1 (0.58) | — | |
| SCHEMBL4411081 | 0.76 | KMT2A (0.41) | KMT2AMEN1TRPV1 | |
| SCHEMBL9872140 | 0.74 | ALDH1A1 (0.49) | KMT2AMEN1TRPV1 | |
| SCHEMBL4403847 | 0.74 | TRPV1 (0.40) | KMT2ATRPV1 | |
| SCHEMBL4405330 | 0.74 | TRPV1 (0.43) | KMT2ATRPV1 | |
| SCHEMBL4405519 | 0.74 | TRPV1 (0.40) | KMT2AMEN1TRPV1 | |
| SCHEMBL4407275 | 0.74 | TRPV1 (0.40) | KMT2AMEN1TRPV1 | |
| SCHEMBL8962480 | 0.74 | ALDH1A1 (0.49) | KMT2AMEN1TRPV1 | |
| SCHEMBL9872644 | 0.74 | ALDH1A1 (0.49) | KMT2AMEN1TRPV1 | |
| SCHEMBL9872505 | 0.74 | ALDH1A1 (0.49) | KMT2AMEN1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576077-B2 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| EP-1716152-B1 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM5 | KMT2A 2760/4885MEN1 1801/4885S1PR2 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.